Treatment of Alcohol Induced Hepatic Injury with REV-ERB Ligands
用 REV-ERB 配体治疗酒精引起的肝损伤
基本信息
- 批准号:8898423
- 负责人:
- 金额:$ 20.25万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2012
- 资助国家:美国
- 起止时间:2012-12-01 至 2015-11-30
- 项目状态:已结题
- 来源:
- 关键词:AddressAdultAgonistAlcohol abuseAlcohol consumptionAlcohol dependenceAlcoholic Fatty LiverAlcoholic HepatitisAlcoholic Liver DiseasesAlcoholsAmericanAnimal ModelAnti-Cytokine TherapyAnti-Inflammatory AgentsAnti-inflammatoryCessation of lifeCholesterolChronicChronic HepatitisCircadian RhythmsCirrhosisClinicalDataDevelopmentDietDiseaseEnzymesFatty LiverFatty acid glycerol estersFibrosisGene ExpressionGenesGlucoseGoalsHealthHeavy DrinkingHepaticHepatitisIndividualInjuryLeadLigandsLiverLiver diseasesMediatingMetabolicMetabolic DiseasesMusNuclear ReceptorsNutritional SupportObesityPathogenesisPatientsPatternPlayPreventionProductionPublic HealthRegulationRelapseResearchRisk FactorsRodentRoleStagingSteroidsSymptomsTestingUnited Statesalcohol abstinencealcohol exposurebasedrinkingfeedingin vivoinnovationlipid biosynthesislipid metabolismliver injurymeetingsnon-alcoholic fatty livernoveloxidation
项目摘要
DESCRIPTION (provided by applicant): Alcoholic liver disease (ALD) is a significant public health concern in the United States. ALD ranges from simple steatosis (fatty liver) to cirrhosis and patients with ALD also may share risk factors for simultaneous injury from non-alcoholic fatty liver disease (NAFLD), which is a significant concern given its association with high fat diets and obesity common in our culture. Approximately 7.4% of adult Americans were estimated to meet the DSMIV criteria for alcohol abuse of alcohol dependence in 1994 and in 2003 44% of all deaths attributed to liver disease were due to alcohol abuse. ALD develops in stages beginning with fatty liver (steatosis) and sequentially progressing to alcoholic hepatitis and then chronic hepatitis with fibrosis (cirrhosis). Alcoholic fatty liver is most typically withot symptoms and is reversible with abstinence from alcohol for about 6 weeks, but in as many as 5-15% of individuals with steatosis will progress to hepatitis and cirrhosis even despite eliminating alcohol consumption. The first step in ALD is development of hepatic steatosis and this is due to significant alterations in lipid metabolism mediated by excessive alcohol consumption. Currently, there are no therapies that directly address development of alcohol-induced fatty liver. Alterations in the circadian rhythm of gene expression (both clock genes and metabolic genes) are associated with alterations in lipid metabolism in the liver. We hypothesize that chronic alcohol administration to mice will lead to alterations in the normal circadian rhythm
of core clock genes as well as genes encoding key enzymes involved in lipogenesis and ß-oxidation. Furthermore, we have developed the first synthetic agonists (that have in vivo activity)
for the nuclear receptors, REV-ERBα and REV-ERBß, which play a critical role in regulation of the mammalian clock. Our preliminary data indicates that these agonists have the ability to alter the circadian rhythm of both core clock and lipogenic genes in the liver and additionally, reduce hepatic steatosis in mice fed a high fat diet. Thus, we hypothesize that REV-ERB agonists may hold utility in treatment of ALD due to their potential ability to reduce alcohol-induced hepatic steatosis and prevention of further progression of hepatic injury due to ALD. In order to address our goal and test our hypothesis, we propose two specific aims: 1. Determine if hepatic steatosis induced by alcohol can be reduced by treatment with REV-ERB agonists and 2. Determine if disturbances in the circadian rhythm of gene expression induced by chronic ethanol exposure can be normalized by treatment with REV-ERB agonists. The proposed research is highly innovative since it examines a completely novel mechanism for treatment for ALD. Furthermore, the proposed research has the potential for high impact since the compounds (or derivatives thereof) may be used clinically to treat ALD.
描述(由申请人提供):酒精性肝病(ALD)在美国是一个重要的公共卫生问题。ALD范围从单纯脂肪变性(脂肪肝)到肝硬化,并且ALD患者也可能具有非酒精性脂肪性肝病(NAFLD)同时损伤的危险因素,这是一个值得关注的问题,因为它与我们文化中常见的高脂肪饮食和肥胖有关。据估计,1994年约有7.4%的成年美国人符合DSMIV关于酒精滥用或酒精依赖的标准,2003年44%的肝脏疾病死亡是由于酒精滥用。ALD的发展分阶段开始于脂肪肝(脂肪变性),随后发展为酒精性肝炎,然后是慢性肝纤维化(肝硬化)。酒精性脂肪肝最典型的症状是没有症状的,并且在戒酒约6周后是可逆的,但即使不饮酒,仍有多达5-15%的脂肪变性患者会发展为肝炎和肝硬化。ALD的第一步是肝脏脂肪变性的发展,这是由于过度饮酒介导的脂质代谢的显著改变。目前,还没有直接治疗酒精性脂肪肝的方法。基因表达昼夜节律的改变(时钟基因和代谢基因)与肝脏脂质代谢的改变有关。我们假设小鼠长期饮酒会导致正常昼夜节律的改变
项目成果
期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Thomas P Burris其他文献
How to Make Glucocorticoids Safer.
- DOI:
10.1124/jpet.123.001931 - 发表时间:
2024-02 - 期刊:
- 影响因子:0
- 作者:
Thomas P Burris - 通讯作者:
Thomas P Burris
PPARα ligands make memories
过氧化物酶体增殖物激活受体α配体形成记忆
- DOI:
10.1038/nchembio.2241 - 发表时间:
2016-11-15 - 期刊:
- 影响因子:13.700
- 作者:
Thomas P Burris - 通讯作者:
Thomas P Burris
Thomas P Burris的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Thomas P Burris', 18)}}的其他基金
Exercise Mimetics for Dementia and Alzheimer's Disease
治疗痴呆和阿尔茨海默病的模拟运动
- 批准号:
10586188 - 财政年份:2023
- 资助金额:
$ 20.25万 - 项目类别:
Targeting REV-ERB to treat Alzheimer's disease
靶向 REV-ERB 治疗阿尔茨海默病
- 批准号:
10675294 - 财政年份:2019
- 资助金额:
$ 20.25万 - 项目类别:
ERRgamma Agonists to Treat Muscular Dystrophy
ERRgamma 激动剂治疗肌营养不良症
- 批准号:
9176946 - 财政年份:2016
- 资助金额:
$ 20.25万 - 项目类别:
REV-ERB ligands for treatment of anxiety disorders
用于治疗焦虑症的 REV-ERB 配体
- 批准号:
8915743 - 财政年份:2012
- 资助金额:
$ 20.25万 - 项目类别:
REV-ERB ligands for treatment of anxiety disorders
用于治疗焦虑症的 REV-ERB 配体
- 批准号:
8237792 - 财政年份:2012
- 资助金额:
$ 20.25万 - 项目类别:
REV-ERB ligands for treatment of anxiety disorders
用于治疗焦虑症的 REV-ERB 配体
- 批准号:
8578608 - 财政年份:2012
- 资助金额:
$ 20.25万 - 项目类别:
Treatment of Alcohol Induced Hepatic Injury with REV-ERB Ligands
用 REV-ERB 配体治疗酒精引起的肝损伤
- 批准号:
8444102 - 财政年份:2012
- 资助金额:
$ 20.25万 - 项目类别:
REV-ERB ligands for treatment of anxiety disorders
用于治疗焦虑症的 REV-ERB 配体
- 批准号:
9116001 - 财政年份:2012
- 资助金额:
$ 20.25万 - 项目类别:
Development of ROR ligands for treatment of circadian rhythm disorders
开发用于治疗昼夜节律紊乱的 ROR 配体
- 批准号:
8370510 - 财政年份:2010
- 资助金额:
$ 20.25万 - 项目类别:
Development of ROR ligands for treatment of circadian rhythm disorders
开发用于治疗昼夜节律紊乱的 ROR 配体
- 批准号:
8209001 - 财政年份:2010
- 资助金额:
$ 20.25万 - 项目类别:
相似海外基金
Co-designing a lifestyle, stop-vaping intervention for ex-smoking, adult vapers (CLOVER study)
为戒烟的成年电子烟使用者共同设计生活方式、戒烟干预措施(CLOVER 研究)
- 批准号:
MR/Z503605/1 - 财政年份:2024
- 资助金额:
$ 20.25万 - 项目类别:
Research Grant
Early Life Antecedents Predicting Adult Daily Affective Reactivity to Stress
早期生活经历预测成人对压力的日常情感反应
- 批准号:
2336167 - 财政年份:2024
- 资助金额:
$ 20.25万 - 项目类别:
Standard Grant
RAPID: Affective Mechanisms of Adjustment in Diverse Emerging Adult Student Communities Before, During, and Beyond the COVID-19 Pandemic
RAPID:COVID-19 大流行之前、期间和之后不同新兴成人学生社区的情感调整机制
- 批准号:
2402691 - 财政年份:2024
- 资助金额:
$ 20.25万 - 项目类别:
Standard Grant
Elucidation of Adult Newt Cells Regulating the ZRS enhancer during Limb Regeneration
阐明成体蝾螈细胞在肢体再生过程中调节 ZRS 增强子
- 批准号:
24K12150 - 财政年份:2024
- 资助金额:
$ 20.25万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Migrant Youth and the Sociolegal Construction of Child and Adult Categories
流动青年与儿童和成人类别的社会法律建构
- 批准号:
2341428 - 财政年份:2024
- 资助金额:
$ 20.25万 - 项目类别:
Standard Grant
Understanding how platelets mediate new neuron formation in the adult brain
了解血小板如何介导成人大脑中新神经元的形成
- 批准号:
DE240100561 - 财政年份:2024
- 资助金额:
$ 20.25万 - 项目类别:
Discovery Early Career Researcher Award
Laboratory testing and development of a new adult ankle splint
新型成人踝关节夹板的实验室测试和开发
- 批准号:
10065645 - 财政年份:2023
- 资助金额:
$ 20.25万 - 项目类别:
Collaborative R&D
Usefulness of a question prompt sheet for onco-fertility in adolescent and young adult patients under 25 years old.
问题提示表对于 25 岁以下青少年和年轻成年患者的肿瘤生育力的有用性。
- 批准号:
23K09542 - 财政年份:2023
- 资助金额:
$ 20.25万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Identification of new specific molecules associated with right ventricular dysfunction in adult patients with congenital heart disease
鉴定与成年先天性心脏病患者右心室功能障碍相关的新特异性分子
- 批准号:
23K07552 - 财政年份:2023
- 资助金额:
$ 20.25万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Issue identifications and model developments in transitional care for patients with adult congenital heart disease.
成人先天性心脏病患者过渡护理的问题识别和模型开发。
- 批准号:
23K07559 - 财政年份:2023
- 资助金额:
$ 20.25万 - 项目类别:
Grant-in-Aid for Scientific Research (C)